Role of molecular genetics in hemophilia: From diagnosis to therapy

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 1, 2012, Pages 64-78

  Jayandharan, Giridhararao ^a   Srivastava, Arun ^b   Srivastava, Alok ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

gene therapy; genetic diagnosis; hemophilia; inhibitor; phenotype; variation

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR 2; ADENO ASSOCIATED VIRUS VECTOR F8; ADENO ASSOCIATED VIRUS VECTOR F9; PARVOVIRUS VECTOR; SELF COMPLEMENTARY ADENO ASSOCIATED VIRUS VECTOR 8; SELF COMPLEMENTARY ADENO ASSOCIATED VIRUS VECTOR PROTEIN PHOSPHATASE 5; SINGLE STRANDED ADENO ASSOCIATED VIRUS VECTOR; SINGLE STRANDED ADENO ASSOCIATED VIRUS VECTOR 2; UNCLASSIFIED DRUG;

CONFERENCE PAPER; HEMOPHILIA; INHERITANCE; LINKAGE ANALYSIS; MOLECULAR GENETICS; PRIORITY JOURNAL; VIRAL GENE THERAPY;

EID: 84857004755     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1300953     Document Type: Conference Paper

References (134)

1. OMahoney B. Global haemophilia care challenge and opportunities: World Federation of Hemophilia.: 2002
2. Gitschier J, Wood WI, Goralka TM., et al. Characterization of the human factor VIII gene. Nature: 1984; 312 5992 326 330 (Pubitemid 15209308)
3. Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry: 1985; 24 14 3736 3750 (Pubitemid 15011912)
4. Drayna D, White R. The genetic linkage map of the human X chromosome. Science: 1985; 230 4727 753 758 (Pubitemid 16193963)
5. Gitschier JWW, Wood WI, Goralka TM., et al. Characterization of the human factor VIII gene. Nature: 1984; 312 5992 326 330 (Pubitemid 15209308)
6. Leuer M, Oldenburg J, Lavergne JM., et al. Somatic mosaicism in hemophilia A: a fairly common event. Am J Hum Genet: 2001; 69 1 75 87 (Pubitemid 32614020)
7. Peake IR, Lillicrap DP, Boulyjenkov V., et al. Haemophilia: strategies for carrier detection and prenatal diagnosis. Bull World Health Organ: 1993; 71 3-4 429 458
8. Peyvandi F. Carrier detection and prenatal diagnosis of hemophilia in developing countries. Semin Thromb Hemost: 2005; 31 5 544 554 (Pubitemid 41642568)
9. Lalloz MR, Schwaab R, McVey JH, Michaelides K, Tuddenham EG. Haemophilia A diagnosis by simultaneous analysis of two variable dinucleotide tandem repeats within the factor VIII gene. Br J Haematol: 1994; 86 4 804 809 (Pubitemid 24194439)
10. Jayandharan G, Shaji RV, George B, Chandy M, Srivastava A. Informativeness of linkage analysis for genetic diagnosis of haemophilia A in India. Haemophilia: 2004; 10 5 553 559 (Pubitemid 39317766)
11. de Carvalho FM, de Vargas Wolfgramm E, Paneto GG., et al. Analysis of factor VIII polymorphic markers as a means for carrier detection in Brazilian families with haemophilia A. Haemophilia: 2007; 13 4 409 412 (Pubitemid 47040171)
12. Ranjan R, Biswas A, Kannan M, Meena A, Deka D, Saxena R. Prenatal diagnosis of haemophilia A by chorionic villus sampling and cordocentesis: all India Institute of Medical Science experience. Vox Sang: 2007; 92 1 79 84 (Pubitemid 44950353)
13. Fang Y, Wang XF, Dai J, Wang HL. A rapid multifluorescent polymerase chain reaction for genetic counselling in Chinese haemophilia A families. Haemophilia: 2006; 12 1 62 67
14. Liu Q, Nozari G, Sommer SS. Single-tube polymerase chain reaction for rapid diagnosis of the inversion hotspot of mutation in hemophilia A. Blood: 1998; 92 4 1458 1459 (Pubitemid 28369064)
15. Bagnall RD, Waseem N, Green PM, Giannelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood: 2002; 99 1 168 174 (Pubitemid 34532979)
16. Bowen DJ. Haemophilia A and haemophilia B: molecular insights. Mol Pathol: 2002; 55 2 127 144
17. Peyvandi F, Jayandharan G, Chandy M., et al. Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia: 2006; 12 Suppl 3 82 89
18. Jeffreys AJ, Royle NJ, Wilson V, Wong Z. Spontaneous mutation rates to new length alleles at tandem-repetitive hypervariable loci in human DNA. Nature: 1988; 332 6161 278 281 (Pubitemid 18076662)
19. Williams IJ, Abuzenadah A, Winship PR., et al. Precise carrier diagnosis in families with haemophilia A: use of conformation sensitive gel electrophoresis for mutation screening and polymorphism analysis. Thromb Haemost: 1998; 79 4 723 726 (Pubitemid 28163842)
20. Pieneman WC, Deutz-Terlouw PP, Reitsma PH, Brit E. Screening for mutations in haemophilia A patients by multiplex PCR-SSCP, Southern blotting and RNA analysis: the detection of a genetic abnormality in the factor VIII gene in 30 out of 35 patients. Br J Haematol: 1995; 90 2 442 449
21. Kogan S, Gitschier J. Mutations and a polymorphism in the factor VIII gene discovered by denaturing gradient gel electrophoresis. Proc Natl Acad Sci U S A: 1990; 87 6 2092 2096
22. Herbert O, Trossart M, Boisseau P, Fressinaud E, Gerson F. Evaluation of denaturing high-performance liquid chromatography (DHPLC) in the screening of mutations in hemophilia B patients. J Thromb Haemost: 2004; 2 12 2267 2269 (Pubitemid 40185793)
23. Jayandharan G, Shaji RV, Chandy M, Srivastava A. Identification of factor IX gene defects using a multiplex PCR and CSGE strategy-a first report. J Thromb Haemost: 2003; 1 9 2051 2054
24. Jayandharan G, Shaji RV, Baidya S, Nair SC, Chandy M, Srivastava A. Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions. Haemophilia: 2005; 11 5 481 491 (Pubitemid 41283117)
25. Jayandharan G, Nelson EJ, Baidya S, Chandy M, Srivastava A. A new multiplex PCR and conformation-sensitive gel electrophoresis strategy for mutation detection in the platelet glycoprotein alphaIIb and beta3 genes. J Thromb Haemost: 2007; 5 1 206 209 (Pubitemid 44921095)
26. Silva Pinto C, Fidalgo T, Salvado R., et al. Molecular diagnosis of haemophilia A at Centro Hospitalar de Coimbra in Portugal: study of 103 families - 15 new mutations. Haemophilia: 2012; 18 1 129 138
27. Oldenburg J, El-Maarri O. New insight into the molecular basis of hemophilia A. Int J Hematol: 2006; 83 2 96 102 (Pubitemid 44227954)
28. Goodeve AC. Another step towards understanding hemophilia A molecular pathogenesis. J Thromb Haemost: 2010; 8 12 2693 2695
29. Tizzano EF, Vencesl A, Baena M., et al. First report of two independent point factorVIII mutations in a family with haemophilia a: a word of caution for carrier diagnosis. Thromb Haemost: 2005; 94 3 675 677 (Pubitemid 41300869)
30. Ogata K, Selvaraj SR, Miao HZ, Pipe SW. Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping. J Thromb Haemost: 2011; 9 6 1183 1190
31. Berber E, Leggo J, Brown C., et al. DNA microarray analysis for the detection of mutations in hemophilia A. J Thromb Haemost: 2006; 4 8 1756 1762 (Pubitemid 44144803)
32. Chan K, Sasanakul W, Mellars G., et al. Detection of known haemophilia B mutations and carrier testing by microarray. Thromb Haemost: 2005; 94 4 872 878 (Pubitemid 41489252)
33. Tizzano EF, Barcel MJ, Baena M., et al. Rapid identification of female haemophilia A carriers with deletions in the factor VIII gene by quantitative real-time PCR analysis. Thromb Haemost: 2005; 94 3 661 664 (Pubitemid 41300866)
34. Favaloro EJ. Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process. Semin Thromb Hemost: 2005; 31 1 85 89 (Pubitemid 40262141)
35. Perry DJ, Goodeve A, Hill M, Jennings I, Kitchen S, Walker I.; UK NEQAS for Blood Coagulation. The UK National External Quality Assessment Scheme (UK NEQAS) for molecular genetic testing in haemophilia. Thromb Haemost: 2006; 96 5 597 601 (Pubitemid 44782539)
36. Preston FE, Kitchen S, Jennings I, Woods TA. A UK National External Quality Assessment scheme (UK Neqas) for molecular genetic testing for the diagnosis of familial thrombophilia. Thromb Haemost: 1999; 82 5 1556 1557 (Pubitemid 29527657)
37. Favaloro EJ, Bonar R, Sioufi J., et al. RCPA QAP in Haematology. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology. Semin Thromb Hemost: 2005; 31 1 49 58 (Pubitemid 40262137)
38. College of American Pathologists Proficiency Testing Program. http://www.cap.org/apps/cap.portal?-nfpb=true&-pageLabel=home. Accessed on January 2, 2012
39. Preston FE, Lippi G, Favaloro EJ, Jayandharan GR, Edison ES, Srivastava A. Quality issues in laboratory haemostasis. Haemophilia: 2010; 16 Suppl 5 93 99
40. Schramm W, Royal S, Kroner B., et al. for the European haemophilia economic study group. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia: 2002; 8 1 33 43 (Pubitemid 34257917)
41. Molho P, Rolland N, Lebrun T., et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophiles@cch.ap-hop-paris.fr. Haemophilia: 2000; 6 1 23 32 (Pubitemid 30113898)
42. Aledort LM, Haschmeyer RH, Pettersson H.; The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med: 1994; 236 4 391 399 (Pubitemid 24323199)
43. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet: 2003; 361 9371 1801 1809 (Pubitemid 36638432)
44. Pollmann H, Richter H, Ringkamp H, Jürgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr: 1999; 158 Suppl 3 S166 S170 (Pubitemid 30014028)
45. Ramgren O. Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand: 1962; 171 237 242
46. Rainsford SG, Hall A. A three-year study of adolescent boys suffering from haemophilia and allied disorders. Br J Haematol: 1973; 24 5 539 551
47. Blanchette P, Rivard G, Israels S., et al. Association of Hemophilia Clinic Directors of Canada and Canadian Association of Nurses in Hemophilia Care. A survey of factor prophylaxis in the Canadian haemophilia A population. Haemophilia: 2004; 10 6 679 683 (Pubitemid 40028582)
48. Beltrn-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia: 2005; 11 4 326 334 (Pubitemid 41030831)
49. Shima M, Matsumoto T, Fukuda K., et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost: 2002; 87 3 436 441 (Pubitemid 34232485)
50. van Dijk K, van der Bom JG, Lenting PJ., et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica: 2005; 90 4 494 498 (Pubitemid 40592892)
51. Arbini AA, Mannucci PM, Bauer KA. Low prevalence of the factor V Leiden mutation among "severeo" hemophiliacs with a "mildero" bleeding diathesis. Thromb Haemost: 1995; 74 5 1255 1258
52. Escuriola Ettingshausen C, Halimeh S, Kurnik K., et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost: 2001; 85 2 218 220 (Pubitemid 32140563)
53. Ghosh K, Shetty S, Mohanty D. Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay. Haemophilia: 2001; 7 1 9 12 (Pubitemid 32162191)
54. van Dijk K, van der Bom JG, Fischer K, Grobbee DE, van den Berg HM. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost: 2004; 92 2 305 310 (Pubitemid 39172311)
55. Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost: 2008; 34 1 128 141 (Pubitemid 351640888)
56. Jayandharan GR, Nair SC, Poonnoose PM., et al. Polymorphism in factor VII gene modifies phenotype of severe haemophilia. Haemophilia: 2009; 15 6 1228 1236
57. Jayandharan GR, Chapla A, Nair SC., et al. A polymorphism in Interferon gamma gene impacts the extent of joint damage in patients with severe hemophilia. Blood: 2010; 110 A546 (Suppl.) Abstract 546
58. Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol: 2011; 72 4 553 562
59. Ehrenforth S, Kreuz W, Scharrer I., et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet: 1992; 339 8793 594 598
60. Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost: 2003; 29 1 23 30 (Pubitemid 36250260)
61. High KA. Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation. Adv Exp Med Biol: 1995; 386 79 86 (Pubitemid 26079032)
62. Chambost H. Assessing risk factors: prevention of inhibitors in haemophilia. Haemophilia: 2010; 16 Suppl 2 10 15
63. Oldenburg J, Schröder J, Brackmann HH, Müller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol: 2004;; 41 1 Suppl 1 82 88 (Pubitemid 38182722)
64. Fakharzadeh SS, Kazazian HH Jr. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost: 2000; 26 2 167 171 (Pubitemid 30439354)
65. Fay PJ, Jenkins PV. Mutating factor VIII: lessons from structure to function. Blood Rev: 2005; 19 1 15 27 (Pubitemid 39574246)
66. Graw J, Brackmann HH, Oldenburg J, Schneppenheim R, Spannagl M, Schwaab R. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet: 2005; 6 6 488 501 (Pubitemid 40733893)
67. Green PM, Montandon AJ, Bentley DR, Giannelli F. Genetics and molecular biology of haemophilias A and B. Blood Coagul Fibrinolysis: 1991; 2 4 539 565
68. Astermark J, Berntorp E, White GC, Kroner BL.; MIBS Study Group. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia: 2001; 7 3 267 272 (Pubitemid 32471960)
69. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK.; MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood: 2006; 107 8 3167 3172
70. Viel KR, Ameri A, Abshire TC., et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med: 2009; 360 16 1618 1627
71. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK.; MIBS Study Group. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost: 2007; 5 2 263 265 (Pubitemid 46139449)
72. Astermark J, Oldenburg J, Carlson J., et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood: 2006; 108 12 3739 3745 (Pubitemid 44864553)
73. White GC II, Kempton CL, Grimsley A, Nielsen B, Roberts HR. Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs? J Thromb Haemost: 2005; 3 8 1676 1681 (Pubitemid 41716553)
74. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol: 2004; 127 4 379 391 (Pubitemid 39539246)
75. Goodeve A. The incidence of inhibitor development according to specific mutationsand treatment? Blood Coagul Fibrinolysis: 2003; 14 Suppl 1 S17 S21 (Pubitemid 36951877)
76. High KA. The Jeremiah Metzger Lecture: gene therapy for inherited disorders: from Christmas disease to Lebers amaurosis. Trans Am Clin Climatol Assoc: 2009; 120 331 359
77. Donahue RE, Kessler SW, Bodine D., et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med: 1992; 176 4 1125 1135
78. Hacein-Bey-Abina S, Von Kalle C, Schmidt M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science: 2003; 302 5644 415 419 (Pubitemid 37296260)
79. Kohn DB, Sadelain M, Dunbar C., et al. American Society of Gene Therapy (ASGT). American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther: 2003; 8 2 180 187 (Pubitemid 37062828)
80. Blacklow N. Parvoviruses and Human Disease. Boca Raton: CRC Press; 1988
81. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev: 2008; 21 4 583 593
82. Flotte TR. Recent developments in recombinant AAV-mediated gene therapy for lung diseases. Curr Gene Ther: 2005; 5 3 361 366 (Pubitemid 40895020)
83. Kaplitt MG, Feigin A, Tang C., et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinsons disease: an open label, phase I trial. Lancet: 2007; 369 9579 2097 2105 (Pubitemid 46935946)
84. Bainbridge JW, Smith AJ, Barker SS., et al. Effect of gene therapy on visual function in Lebers congenital amaurosis. N Engl J Med: 2008; 358 21 2231 2239 (Pubitemid 351724452)
85. Maguire AM, Simonelli F, Pierce EA., et al. Safety and efficacy of gene transfer for Lebers congenital amaurosis. N Engl J Med: 2008; 358 21 2240 2248 (Pubitemid 351724453)
86. Wang L, Herzog RW. AAV-mediated gene transfer for treatment of hemophilia. Curr Gene Ther: 2005; 5 3 349 360 (Pubitemid 40895019)
87. Gnatenko DV, Saenko EL, Jesty J, Cao LX, Hearing P, Bahou WF. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy. Br J Haematol: 1999; 104 1 27 36 (Pubitemid 29037014)
88. Sarkar R, Xiao W, Kazazian HH Jr. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J Thromb Haemost: 2003; 1 2 220 226
89. Walsh CE, Chao H. Parvovirus-mediated gene transfer for the haemophilias. Haemophilia: 2002; 8 Suppl 2 60 67 (Pubitemid 34498631)
90. Sarkar R, Tetreault R, Gao G., et al. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood: 2004; 103 4 1253 1260 (Pubitemid 38168635)
91. Jiang H, Lillicrap D, Patarroyo-White S., et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood: 2006; 108 1 107 115 (Pubitemid 43990618)
92. Jayandharan GR, Zhong L, Li B, Kachniarz B, Srivastava A. Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther: 2008; 15 18 1287 1293
93. Jayandharan GR, Zhong L, Sack BK., et al. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses. Hum Gene Ther: 2010; 21 3 271 283
94. Monahan PE, Lothrop CD, Sun J., et al. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther: 2010; 18 11 1907 1916
95. Sabatino DE, Lange AM, Altynova ES., et al. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther: 2011; 19 3 442 449
96. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet: 2011; 12 5 341 355
97. Herzog RW, Hagstrom JN, Kung SH., et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A: 1997; 94 11 5804 5809 (Pubitemid 27241852)
98. Snyder RO, Miao CH, Patijn GA., et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet: 1997; 16 3 270 276 (Pubitemid 27280211)
99. Nathwani AC, Gray JT, McIntosh J., et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood: 2007; 109 4 1414 1421 (Pubitemid 46239572)
100. Nathwani AC, Gray JT, Ng CY., et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood: 2006; 107 7 2653 2661
101. Wang L, Takabe K, Bidlingmaier SM, Ill CR, Verma IM. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci U S A: 1999; 96 7 3906 3910 (Pubitemid 29169009)
102. Monahan PE, Samulski RJ, Tazelaar J., et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther: 1998; 5 1 40 49 (Pubitemid 28045068)
103. Niemeyer GP, Herzog RW, Mount J., et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood: 2009; 113 4 797 806
104. Snyder RO, Miao C, Meuse L., et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med: 1999; 5 1 64 70 (Pubitemid 29051000)
105. Manno CS, Chew AJ, Hutchison S., et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood: 2003; 101 8 2963 2972 (Pubitemid 36857981)
106. Kay MA, Manno CS, Ragni MV., et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet: 2000; 24 3 257 261 (Pubitemid 30132193)
107. Manno CS, Pierce GF, Arruda VR., et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med: 2006; 12 3 342 347 (Pubitemid 43355084)
108. Mingozzi F, Maus MV, Hui DJ., et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med: 2007; 13 4 419 422 (Pubitemid 46559826)
109. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther: 2007; 7 5 316 324 (Pubitemid 47595774)
110. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther: 2008; 15 11 808 816 (Pubitemid 351712613)
111. Basner-Tschakarjan E, Mingozzi F, Chen Y, Nathwani AC, Tuddenham EGD, Rosales C, McIntosh MF, Riddell A, Rustagi P, Glader B, Kay MA, Allay J, Coleman J, Sleep S, Gray J, Reiss U, Nienhuis AW, Davidoff AM, High KA. Dose-dependent activation of capsid-specific T cells after AAV serotype 8 vector adminstration in a clinical study for hemophilia B. Molecular Therapy: 2011;;19, Suppl 1:Abstract 602.
112. Mingozzi F, Kleefstra A, Meulenberg J., et al. Modulation of T cell response to the AAV capsid in subjects undergoing intramuscular gene transfer for lipoprotein lipase deficiency. Hum Gene Ther: 2008; 19 10 1090
113. Zhong L, Li B, Mah CS., et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A: 2008; 105 22 7827 7832 (Pubitemid 351872723)
114. Markusic DM, Herzog RW, Aslanidi GV., et al. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther: 2010; 18 12 2048 2056
115. Jayandharan GR, Aslanidi G, Martino AT., et al. Activation of the NF-B pathway by AAV vectors and its implications in immune response and gene therapy. Proc Natl Acad Sci U S A: 2011; 108 9 3743 3748
116. Nathwani AC, Cochrane M, McIntosh J., et al. Enhancing transduction of the liver by adeno-associated viral vectors. Gene Ther: 2009; 16 1 60 69
117. Martino AT, Suzuki M, Markusic DM., et al. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood: 2011; 117 24 6459 6468
118. Ahmed R, Kannan M, Choudhry VP, Saxena R. Does the MTHFR 677T allele alter the clinical phenotype in severe haemophilia A? Thromb Res: 2003; 109 1 71 72 (Pubitemid 36385050)
119. Barnes C, Blanchette V, Lillicrap D., et al. Different clinical phenotype in triplets with haemophilia A. Haemophilia: 2007; 13 2 202 205 (Pubitemid 46237954)
120. Biguzzi E, Mancuso P, Franchi F., et al. Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype. Br J Haematol: 2009; 144 5 803 805
121. Cruz E, Porto G, Morais S, Campos M, de Sousa M. HFE mutations in the pathobiology of hemophilic arthropathy. Blood: 2005; 105 8 3381 3382
122. Grünewald M, Siegemund A, Grünewald A, Konegan A, Koksch M, Griesshammer M. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Haemophilia: 2002; 8 6 768 775 (Pubitemid 35446629)
123. Klintman J, Berntorp E, Astermark J.; MIBS Study Group. Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A. Haemophilia: 2010; 16 1 e210 e215
124. Lee DH, Walker IR, Teitel J., et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost: 2000; 83 3 387 391 (Pubitemid 30148349)
125. Nowak-Göttl U, Escuriola C, Kurnik K., et al. Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations? Hamostaseologie: 2003; 23 1 36 40 (Pubitemid 36197307)
126. Ninivaggi M, Dargaud Y, van Oerle R, de Laat B, Hemker HC, Lindhout T. Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A. J Thromb Haemost: 2011; 9 8 1549 1555
127. Petkova R, Chakarov S, Horvath A, Ganev V, Kremensky I. Coexistence of a common prothrombotic risk factor and hemophilia in the Bulgarian hemophilic population:genotype/phenotype correlations. Balkan J Med Genet: 2001; 4 3-4 37 39
128. Santagostino E, Mancuso ME, Tripodi A., et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost: 2010; 8 4 737 743
129. Schulman S, Eelde A, Holmström M, Sthlberg G, Odeberg J, Blombäck M. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost: 2008; 6 7 1113 1121 (Pubitemid 351859120)
130. Shetty S, Vora S, Kulkarni B., et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol: 2007; 138 4 541 544 (Pubitemid 47063041)
131. Yee DL. Platelets as modifiers of clinical phenotype in hemophilia. Scientific World J: 2006; 6 661 668 (Pubitemid 44086411)
132. van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia: 2005; 11 5 438 443 (Pubitemid 41283110)
133. van Dijk K, van der Bom JG, Fischer K, de Groot PG, van den Berg HM. Phenotype of severe hemophilia A and plasma levels of risk factors for thrombosis. J Thromb Haemost: 2007; 5 5 1062 1064 (Pubitemid 46691738)
134. Nathwani AC, Tuddenham EG, Rangarajan S., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med: 2011; 365 25 2357 2365